Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-04-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Haike Medical Group Co., Ltd. It details the approval of various reports including the 2023 Supervisory Board Work Report, 2023 Financial Report, 2023 Annual Report and its summary, 2023 Internal Control Self-Evaluation Report, 2023 Profit Distribution Proposal, use of idle raised funds, and the 2024 Q1 Report. The document is a formal announcement of the Supervisory Board meeting decisions and approvals, not the reports themselves. It also states that these reports still require shareholder meeting approval. The document length is 1730 characters, which is short and consistent with an announcement rather than a full report. Therefore, this is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of board resolutions and approvals, not the full reports or financial statements themselves.
2024-04-19 Chinese
2023年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2023 Annual Board of Directors Work Report" of 海思科医药集团股份有限公司. It details the activities, meetings, and resolutions of the board of directors throughout the year 2023, including summaries of company performance, board meeting frequency, agenda items, and future outlook. The content focuses on the board's governance and operational oversight rather than presenting full financial statements or audit results. It is a comprehensive report on the board's work rather than a financial report or an announcement. This fits the category of Board/Management Information (MANG), which covers announcements or reports about changes or activities of the board or senior management. The document length is 4427 characters, which is sufficient to be a report rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2024-04-19 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2023 by 海思科医药集团股份有限公司. It discusses the company's internal control systems, evaluation of internal control effectiveness as of December 31, 2023, and the absence of significant deficiencies in financial and non-financial internal controls. The content is detailed and comprehensive, covering governance, risk management, audit, and control procedures. It is not a full annual report (10-K), nor an earnings release or call transcript. It is a standalone report focused on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR). The document length (9431 characters) supports it being a full report rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2023
2024-04-19 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "海思科医药集团股份有限公司2023 年年度报告全文" which translates to "Haisco Pharmaceutical Group Co., Ltd. 2023 Annual Report Full Text." It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, important matters, shareholder information, bond information, and financial statements. The document includes comprehensive financial figures, management analysis, accounting policy changes, and detailed business descriptions. The length is substantial (15,000 characters), and it is the full report, not just an announcement or a summary. The presence of audited financial statements and management discussion confirms it is the official annual report covering the full fiscal year 2023. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-19 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Annual Report on the Deposit and Actual Use of Raised Funds" by 海思科医药集团股份有限公司. It details the company's fundraising activities, including the amount raised, usage of funds, management of raised funds, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial figures related to the raised funds. It is a specialized report focusing on the management and use of capital raised through a non-public stock issuance, rather than a general annual report or earnings release. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (9,320 characters) and detailed financial data support that this is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-04-19 Chinese
独立董事2023年度述职报告（岳琳）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for a pharmaceutical company. It details the independent director's attendance at board meetings, opinions on board resolutions, on-site inspections, protection of investor rights, committee work, and training. The content focuses on governance, director duties, and compliance with regulatory requirements. It does not contain financial statements or earnings data, nor is it an announcement or proxy material. The document is a detailed report on board/management activities and director responsibilities for the year 2023. Therefore, it fits best under Board/Management Information (MANG). The document length is 2039 characters, which is consistent with a detailed report rather than a brief announcement or certification.
2024-04-19 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.